SCM-Bios Lung Therapeutics SPV, LP
Bios Partners · adviser of record: Steelhead Capital Management, LLC · 2014 vintage
SCM-Bios Lung Therapeutics SPV, LP is a 2014 venture fund managed by Bios Partners. It reported $8.8mm in gross assets at year-end 2022, against a peak of $8.9mm in 2021.
- Latest value held
- $8.8mm year-end 2022
- Peak
- $8.9mm year-end 2021
- Fund size
- Not on file
Value held by year-end
Gross asset value reported on Form ADV at each year-end. Open in the Fund Tracker
| Year-end | Gross assets | ÷ size | Change |
|---|---|---|---|
| 2022 | $8.8mm | – | -1% |
| 2021 | $8.9mm | – | +1% |
| 2020 | $8.8mm | – | +7% |
| 2019 | $8.3mm | – | +15% |
| 2018 | $7.2mm | – | +59% |
| 2017 | $4.5mm | – | +0% |
| 2016 | $4.5mm | – | +0% |
| 2015 | $4.5mm | – | +126% |
| 2014 | $2mm | – | – |
Other funds from Bios Partners
- Bios Sirpant CO-Invest I, LP 2021
- Bios Sirpant CO-Invest I QP, LP 2021
- Bios Actuate CO-Invest II, LP 2020
- Bios Onl CO-Invest I, LP 2020
- Bios Actuate CO-Invest III, LP 2020
- Bios Fund III QP, LP 2019
- Bios Fund III NT, LP 2019
- Bios Fund III, LP 2019
- Bios Lti CO-Invest III QP, LP 2018
- Bios Lti CO-Invest III, LP 2018
- Bios Azitra CO-Invest I, LP 2018
- Bios Immusoft CO-Invest I, LP 2018
About these numbers
Gross asset value is what the manager reports holding in the fund at each fiscal year-end, on SEC Form ADV, Schedule D. It includes the GP’s own commitment and is before carried interest, so it is not the LPs’ net return, and it does not show cash already distributed. A fall in value can mean distributions, markdowns or both. Fund size is the amount sold reported on Form D, which for some funds reflects only a first close. Private fund ID 805-5525441713. Data updated October 13, 2026.
Is this your fund?
Spot an error and email a correction. Facing DPI pressure? See how distribution financing works.